tiprankstipranks
Advertisement
Advertisement

VNDA Stock Latest News

Vanda Pharmaceuticals price target lowered to $12 from $17 at B. Riley
The FlyVanda Pharmaceuticals price target lowered to $12 from $17 at B. Riley
2h ago
VNDA
Vanda Pharmaceuticals price target lowered to $20 from $21 at H.C. Wainwright
PremiumThe Fly
Vanda Pharmaceuticals price target lowered to $20 from $21 at H.C. Wainwright
4h ago
VNDA
Vanda Pharmaceuticals Balances Strong Growth With Rising Losses
PremiumCompany Announcements
Vanda Pharmaceuticals Balances Strong Growth With Rising Losses
5d ago
VNDA
Vanda Pharmaceuticals reports Q2 EPS ($1.04) vs. (46c) last year
PremiumThe Fly
Vanda Pharmaceuticals reports Q2 EPS ($1.04) vs. (46c) last year
5d ago
VNDA
Vanda Pharmaceuticals sees FY26 revenue $240M-$290M, consensus $262.1M
PremiumThe Fly
Vanda Pharmaceuticals sees FY26 revenue $240M-$290M, consensus $262.1M
5d ago
VNDA
VNDA Upcoming Earnings Report: What to Expect?
PremiumPre-EarningsVNDA Upcoming Earnings Report: What to Expect?
7d ago
VNDA
Vanda announces EMA positive opinion for orphan drug designation of Imsidolimab
Premium
The Fly
Vanda announces EMA positive opinion for orphan drug designation of Imsidolimab
25d ago
VNDA
Buy Rating Reaffirmed as Vanda’s Regulatory Catalysts Support Unchanged $21 Price Target
Premium
Ratings
Buy Rating Reaffirmed as Vanda’s Regulatory Catalysts Support Unchanged $21 Price Target
1M ago
VNDA
Vanda Pharmaceuticals announces Rare Pediatric Disease Designation for VCA-894A
PremiumThe Fly
Vanda Pharmaceuticals announces Rare Pediatric Disease Designation for VCA-894A
1M ago
VNDA
Vanda Shareholders Approve Directors, Auditor and Compensation Plans
PremiumCompany Announcements
Vanda Shareholders Approve Directors, Auditor and Compensation Plans
2M ago
8K
VNDA
Vanda Pharmaceuticals’ imsidolimab granted orphan drug designation in Japan
PremiumThe Fly
Vanda Pharmaceuticals’ imsidolimab granted orphan drug designation in Japan
3M ago
VNDA
Vanda Pharmaceuticals price target lowered to $21 from $24 at H.C. Wainwright
PremiumThe Fly
Vanda Pharmaceuticals price target lowered to $21 from $24 at H.C. Wainwright
3M ago
VNDA
Vanda Pharmaceuticals Bets Big on Growth Pipeline
PremiumCompany AnnouncementsVanda Pharmaceuticals Bets Big on Growth Pipeline
3M ago
VNDA
Vanda Pharmaceuticals reports Q1 EPS (82c) vs. (50c) last year
Premium
The Fly
Vanda Pharmaceuticals reports Q1 EPS (82c) vs. (50c) last year
3M ago
VNDA
Vanda Pharmaceuticals raises FY26 revenue view to $240M-$290M from $230-$260M
Premium
The Fly
Vanda Pharmaceuticals raises FY26 revenue view to $240M-$290M from $230-$260M
3M ago
VNDA
Vanda Pharmaceuticals announces U.S. commercial availability of Nereus
PremiumThe Fly
Vanda Pharmaceuticals announces U.S. commercial availability of Nereus
3M ago
VNDA
AnaptysBio price target lowered to $93 from $95 at Piper Sandler
PremiumThe Fly
AnaptysBio price target lowered to $93 from $95 at Piper Sandler
3M ago
GSK
ANAB
VNDA Earnings this Week: How Will it Perform?
PremiumPre-Earnings
VNDA Earnings this Week: How Will it Perform?
3M ago
VNDA
Vanda Pharmaceuticals announces commercial availability for Nereus
PremiumThe Fly
Vanda Pharmaceuticals announces commercial availability for Nereus
3M ago
VNDA
Vanda Pharmaceuticals Adds Independent Director to Strengthen Board
PremiumCompany AnnouncementsVanda Pharmaceuticals Adds Independent Director to Strengthen Board
4M ago
8K
VNDA
AnaptysBio price target lowered to $60 from $90 at UBS
Premium
The Fly
AnaptysBio price target lowered to $60 from $90 at UBS
4M ago
GSK
ANAB
Geron appoints Timothy Williams as chief legal officer
Premium
The Fly
Geron appoints Timothy Williams as chief legal officer
4M ago
GERN
VNDA

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >